Declaration statement: Dr. Serretti is or has been a consultant/speaker for: Abbott, Astra Zeneca, Clinical Data, Boheringer, Bristol Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Lundbeck, Pfizer, Sanofi, and Servier. The other authors declare that they have no conflicts of interest.
Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research
Article first published online: 12 JUL 2013
Copyright © 2013 Wiley Periodicals, Inc.
American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Volume 162, Issue 6, pages 487–520, September 2013
How to Cite
2013. Pharmacogenetics of Antidepressant Drugs: An Update After Almost 20 Years of Research. Am J Med Genet Part B 162B:487–520., , .
- Issue published online: 9 AUG 2013
- Article first published online: 12 JUL 2013
- Manuscript Accepted: 19 JUN 2013
- Manuscript Received: 4 AUG 2012
Additional supporting information may be found in the online version of this article at the publisher's web-site.
|ajmgb32184-sm-0001-SuppTab-S1.docx||76K||TABLE SI. Summary of the Pharmacogenetic Association Studies Focused on Antidepressant Induced Side Effects. Polymorphisms which were investigated by at least three independent studies were reported, according to their order of appearance in the main text. Results were labeled as negative when no association was reported between antidepressant induced side effects and the polymorphism per se. AD = antidepressant.|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.